Authors
Gitelson D.G.1, 2, Faibushevich A.G.1, Maximkin D.A.1, Veretnik G.I.1, Vasiliev A.E.2, Gitelson E.A.1, Danishian K.I.2
1 RUDN University, Moscow
2 National Research Center for Hematology, Moscow
Abstract
The coronary artery stenting is a common and effective endovascular treatment for various forms of coronary artery disease (CAD). In most cases prescribed dual antiplatelet therapy (DAPT) helps prevent stent thrombosis (ST). However, the effectiveness of DAPT is rarely monitored. Despite there are 0.6-2% chances in the first year of having ST with high mortality rate after coronary artery stenting. We have seen several cases of acute ST in our practice. Here is a clinical observation.
Keywords: platelet aggregation, antiplatelet therapy, coronary artery stenting, coronary artery disease.
References
1. Frolova NS, Shakhnovich RM, Sirotkina OV, et al. Clopidogrel resistance in patients with acute coronary syndrome. Ter Arkh. 2010;82(8):14–20. (In Russ).
2. Mirzaev KB, Andreev DA, Sychev DA. Evaluation of platelet aggregation in clinical practice. Rational pharmacotherapy in cardiology. 2015;11(1):85–91. (In Russ).] doi: 10.20996/1819-6446-2015-11-1-85-91.
3. Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35(4):209–215. doi: 10.1093/eurheartj/eht375.
4. Asher E, Abu-Much A, Goldenberg I, et al. Incidence and clinical features of early stent thrombosis in the era of new P2Y12 inhibitors (PLATIS-2). PLoS One. 2016;11(6):e0157437. doi: 10.1371/journal.pone.0157437.
5. Brodie B, Pokharel Y, Garg A, et al. Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2012;5(10):1043–1051. doi: 10.1016/j.jcin.2012.06.013.
6. Buchanan GL, Basavarajaiah S, Chieffo A. Stent thrombosis: incidence, predictors and new technologies. Thrombosis. 2012;2012:956–962. doi: 10.1155/2012/956962.
7. Byrne RA, Serruys PW, Baumbach A, et al. Report of a European Society of Cardiology — European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J. 2015; 36(38):2608–2620. doi: 10.1093/eurheartj/ehv203.
8. Cayla G, Hulot JS, O’Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306 (16):1765–1774. doi: 10.1001/jama.2011.1529.
9. Centemero MP, Stadler JR. Stent thrombosis: an overview expert review. Expert Rev Cardiovasc Ther. 2012;10(5):599–615. doi: 10.1586/erc.12.38.
10. Chen W, Wu Y, Hu Y. Early (≤ 30 Days), late (31-360 Days) and very late (> 360 Days) stent thrombosis in patients with insulin-treated versus non-insulin-treated type 2 diabetes mellitus: a meta-analysis. Diabetes Ther. 2018;9(3):1113–1124. doi: 10.1007/s13300-018-0425-1.
11. D’Ascenzo F, Bollati M, Clementi F, et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013;167(2):575–584. doi: 10.1016/j.ijcard.2012.01.080.
12. Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e89S–e119S. doi: 10.1378/chest.11-2293.
13. Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol. 2010;56(17):1357–1365. doi: 10.1016/j.jacc.2010.07.016.
14. who.int [Internet]. Information bulletin of WHO. Top 10 causes of death worldwide [updated 2018 May 24; cited 2019 Nov 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
15. Kubo S, Kadota K, Ichinohe T, et al. Comparison of long-term outcome after percutaneous coronary intervention for stent thrombosis between early, late and very late stent thrombosis. Circ J. 2014;78(1):101–109. doi: 10.1253/circj.cj-13-0780.
16. Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014;35(31):2083–2093. doi: 10.1093/eurheartj/ehu160.
17. Motovska Z, Knot J, Widimsky P. Stent thrombosis — risk assessment and prevention. Cardiovasc Ther. 2010;28(5):e92–100. doi: 10.1111/j.1755-5922.2010.00186.x.
18. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32(23): 2922–2932. doi: 10.1093/eurheartj/ehr373.
19. Sabouret P, Rushton-Smith SK, Kerneis M, et al. Dual antiplatelet therapy: optimal timing, management and duration. Eur Heart J Cardiovasc Pharmacother. 2015;1(3):198–204. doi: 10.1093/ehjcvp/pvv015.
20. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 1996;334(17):1084–1089. doi: 10.1056/NEJM199604253341702.
21. Shah R, Rashid A, Hwang I, et al. Meta-analysis of the relative efficacy and safety of oral P2Y12 inhibitors in patients with acute coronary syndrome. Am J Cardiol. 2017;119(11):1723–1728. doi: 10.1016/j.amjcard.2017.03.011.
22. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicenter registry study. Lancet. 2013;382(9892):614–623. doi: 10.1016/S0140-6736(13)61170-8.
23. Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6 (12):1267–1274. doi: 10.1016/j.jcin.2013.06.015.
24. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–260. doi: 10.1093/ eurheartj/ehx419.
25. van Werkum JW, Heestermans AA, de Korte FI, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation. 2009;119(6):828–834. doi: 10.1161/CIRCULATIONAHA.108.799403.
26. Varenhorst C, Lindholm M, Sarno G, et al. Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents. Clin Res Cardiol. 2018; 107(9):816–823. doi: 10.1007/s00392-018-1252-0.
